Company Overview

Apyx Medical Corporation is a medical technology company focused on developing and commercializing advanced energy-based surgical products. The company operates within the medical device and electrosurgical industries, serving both cosmetic and general surgery markets. Its core value proposition centers on proprietary helium plasma and radiofrequency technologies designed to enable precise tissue cutting, coagulation, and contraction with minimal thermal damage.

The company’s primary revenue driver is its Advanced Energy business, led by the Renuvion product platform, which is used for aesthetic skin tightening and surgical applications. Apyx primarily serves plastic surgeons, dermatologic surgeons, cosmetic physicians, and hospital-based surgeons. The company traces its origins to 1997 under the name Bovie Medical Corporation, initially focused on electrosurgical instruments. It later rebranded to Apyx Medical Corporation to reflect its strategic shift toward advanced plasma-based technologies and aesthetic-focused innovation.

Business Operations

Apyx Medical operates through a single-reportable operating segment focused on the development, manufacturing, and sale of advanced electrosurgical devices and consumables. Revenue is generated through capital equipment sales, disposable handpieces, and recurring consumable products associated with its energy platforms. The company maintains direct sales operations in the United States and utilizes distributors for certain international markets.

The company controls proprietary technologies combining radiofrequency energy with helium plasma, which underpin its flagship Renuvion system. Manufacturing is primarily outsourced to third-party contract manufacturers, while research and development, regulatory affairs, and quality assurance are managed internally. Apyx does not report material joint ventures, but it maintains commercial distribution relationships and regulatory partnerships to support global market access.

Strategic Position & Investments

Apyx Medical’s strategy is centered on expanding clinical indications, driving adoption of its Renuvion platform, and increasing recurring revenue from consumables. Key growth initiatives include investment in clinical studies, regulatory submissions, and post-market surveillance to support expanded labeling and international approvals. The company has also focused on physician education and training programs to increase utilization within aesthetic and surgical practices.

Historically, Apyx has pursued selective acquisitions and technology investments aligned with energy-based surgical innovation, though its growth strategy has primarily emphasized internal product development rather than large-scale M&A. The company continues to invest in next-generation handpieces and software enhancements designed to improve procedural outcomes and workflow efficiency, particularly within minimally invasive and cosmetic procedures.

Geographic Footprint

Apyx Medical is headquartered in Florida, United States, with its primary commercial operations concentrated in North America. The United States represents the company’s largest revenue-generating market, supported by a direct sales force targeting aesthetic and surgical practitioners.

Internationally, Apyx has market presence in Europe, Asia-Pacific, Latin America, and the Middle East through third-party distributors and regulatory partners. While international revenue represents a smaller portion of total sales compared to the U.S., global expansion remains a strategic priority, particularly in regions with growing demand for aesthetic and minimally invasive surgical procedures.

Leadership & Governance

Apyx Medical is led by an executive team with experience in medical devices, commercialization, and regulatory-driven industries. Leadership emphasizes disciplined growth, regulatory compliance, and innovation in advanced energy technologies, with a strategic focus on long-term shareholder value and clinical credibility.

Key executives include:

• Charlie Goodwin – Chief Executive Officer
• Scott A. Brubaker – Chief Financial Officer
• Aaron Brinson – President
• Chris Carlton – Chief Operating Officer
• Michael Moglia – Vice President of Sales

The company is governed by a board of directors responsible for oversight of strategy, risk management, and regulatory compliance, consistent with public company governance standards.